Acino: Mitteilung zu Oxycodon und zum Ausblick 2010

27.12.2010 | von Acino International AG

27.12.2010, Die überwältigende Mehrheit der Gerichtsentscheidungen zu Oxycodon (Originalpräparat: Oxycontin / Oxygesic von Mundipharma) bei den Patentstreitigkeiten zwischen Mundipharma und Acinos Lizenznehmern fiel zugunsten von Acino und ihren Vermarktungspartnern aus. Bestärkt wird der Rechtsstandpunkt von Acino durch das erst jüngst am 21. Dezember 2010 ergangene Urteil des Helsinki District Court in Finnland, welches jegliche Patentverletzung sowie eines der Klagepatente verneinte, dies nachdem das finnische Patentamt das andere Klagepatente bereits zuvor vollumfänglich für nichtig erklärt hatte.

Über Acino International AG:

Acino is part of Arcera, a global company in the life sciences sector headquartered in Abu Dhabi, United Arab Emirates. Arcera was established by ADQ, an Abu Dhabi- based investment and holding company, to build a global life sciences powerhouse poised to make significant contributions to realising the UAE’s aspiration to emerge as a frontrunner in science and technology. To learn more about Arcera, please visit www.arceralifesciences.com.

Established in 1836, today Acino has a global footprint with a clear focus on over 90 high-growth markets. Our company has evolved significantly over the past decades, and we are pleased to celebrate our cultural and geographic diversity.?

As a leader in advanced drug delivery technologies with a focus on modified-release and dispersible forms, for which we also hold patents, we are renowned for the quality of products, our people and our service.